Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 2
Submit an article Journal homepage
235
Views
18
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study

Heather E. Eve Department of Haematology, Derriford Hospital, Plymouth, UK
,
David Linch Department of Haematology, University College Hospital, London, UK
,
Wendi Qian Cancer Research UK and UCL Cancer Trials Centre, London, UK
,
Moira Ross Cancer Research UK and UCL Cancer Trials Centre, London, UK
,
John F. Seymour Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Victoria, Australia
,
Paul Smith Cancer Research UK and UCL Cancer Trials Centre, London, UK
,
Lindsey Stevens Cancer Research UK and UCL Cancer Trials Centre, London, UK
&
Dr. Simon A. J. Rule Department of Haematology, Derriford Hospital, Plymouth, UKCorrespondence[email protected]
 show all
Pages 211-215 | Received 03 Sep 2008, Accepted 13 Dec 2008, Published online: 01 Jul 2009

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Nimish Shah, Constantine Tam, John F. Seymour & Simon Rule. (2015) How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. Leukemia & Lymphoma 56:6, pages 1599-1610.
Read now
Xiao-xiao Xu, Bei Yan, Zhen-xing Wang, Yong Yu, Xiao-xiong Wu & Yi-zhuo Zhang. (2013) Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy. OncoTargets and Therapy 6, pages 1385-1392.
Read now
Christian Geisler, Arne Kolstad, Anna Laurell, Riikka Räty, For Nordic Lymphoma Group & Mantle Cell Lymphoma Subcommittee. (2009) Mantle cell lymphoma – does primary intensive immunochemotherapy improve overall survival for younger patients?. Leukemia & Lymphoma 50:8, pages 1249-1256.
Read now

Articles from other publishers (15)

Tejas S. Athni & Sara Barmettler. (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Annals of Allergy, Asthma & Immunology 130:6, pages 699-712.
Crossref
Sagun Parakh, Dylan King, Hui K. Gan & Andrew M. Scott. 2020. Current Immunotherapeutic Strategies in Cancer. Current Immunotherapeutic Strategies in Cancer 1 70 .
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle, Robert Edward Hawkins & David Edward Gilham. (2017) CD19 CAR T-cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Molecular Therapy - Oncolytics.
Crossref
A. Prica, F. Baldassarre, L.K. Hicks, K. Imrie, T. Kouroukis & M. Cheung. (2017) Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. Clinical Oncology 29:1, pages e13-e28.
Crossref
Andre Goy. (2016) Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1345-1370.
Crossref
C. P. Escalante, Y. C. Chang, K. Liao, T. Rouleau, J. Halm, P. Bossi, S. Bhadriraju, N. Brito-Dellan, S. Sahai, S. W. Yusuf, A. Zalpour & L. S. Elting. (2016) Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer 24:9, pages 4057-4074.
Crossref
Ahmad Salimi, Mehryar Habibi Roudkenar, Leila Sadeghi, Alireza Mohseni, Enayatollah Seydi, Nahal Pirahmadi & Jalal Pourahmad. (2015) Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria. Redox Biology 6, pages 461-471.
Crossref
Jennifer Worch, Olga Makarova & Birgit Burkhardt. (2015) Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. Cancers 7:1, pages 305-328.
Crossref
Linda S. Elting, Yu-Chia Chang, Pratibha Parelkar, Christine B. Boers-Doets, Marisol Michelet, Guido Hita, Tanya Rouleau, Catherine Cooksley, Josiah Halm, Madhuri Vithala, Paolo Bossi, Carmen Escalante & Michael T. Brennan. (2013) Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer 21:11, pages 3243-3254.
Crossref
Gabrielle M. Haeusler, Monica A. Slavin, John F. Seymour, Senthil Lingaratnam, Benjamin W. Teh, Constantine S. Tam, Karin A. Thursky & Leon J. Worth. (2013) Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis . European Journal of Haematology 91:2, pages 157-163.
Crossref
Pashtoon M Kasi, Hussein A Tawbi, Chester V Oddis & Hrishikesh S Kulkarni. (2012) Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Critical Care 16:4, pages 231.
Crossref
Daan Dierickx, André Delannoy, Khalid Saja, Gregor Verhoef & Drew Provan. (2011) Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology 86:3, pages 278-291.
Crossref
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell & Rachelle Buchbinder. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2016:4.
Crossref
Theodoros Kelesidis, George Daikos, Dimitrios Boumpas & Sotirios Tsiodras. (2011) Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases 15:1, pages e2-e16.
Crossref
Juan C. Gea-Banacloche. (2010) Rituximab-Associated Infections. Seminars in Hematology 47:2, pages 187-198.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.